Cartalax

Cartalax — Cartilage / Bone Bioregulator

Cartalax is a Khavinson-class short-chain bioregulator peptide that restores youthful gene expression in cartilage / bone tissue.

Peptide Specifications

Parameter	Value
Sequence	Ala-Glu-Asp
Mass	333.3 g/mol
Purity	>98.0%
Target Organ	Cartilage / Bone

Figure 1: Cartalax Organ-Specific Bioregulation

Tissue-Specific Mechanism

1. Drives chondrocyte gene expression in articular cartilage.
2. Upregulates Type II collagen and aggrecan synthesis.
3. Inhibits matrix metalloproteinases degrading existing cartilage.
4. Promotes osteoblast differentiation and mineralization.
5. Normalizes synovial fluid viscosity.

Figure 2: Cartilage / Bone Regeneration Curve

Research Results

• 1: Khavinson peptide for musculoskeletal regeneration.
• 2: Investigated for reversing early-stage osteoarthritis.
• 3: Addresses root cause (matrix degradation) not symptoms.

Cartilage & Musculoskeletal Bioregulator

Cartalax (Ala-Glu-Asp) is a synthetic tripeptide bioregulator targeting cartilage, bone, and musculoskeletal tissue gene expression. Cartilage degeneration is a hallmark of aging, driven by declining chondrocyte metabolic activity, reduced proteoglycan synthesis, and progressive loss of the collagen II/aggrecan matrix that provides articular cartilage with its compressive resilience. Cartalax modulates chondrocyte gene expression to restore the anabolic/catabolic balance that shifts toward degradation with age, supporting cartilage maintenance and potentially slowing osteoarthritis progression.

1. Cartalax enters chondrocyte nuclei and modulates chromatin accessibility at promoter regions of extracellular matrix genes (COL2A1, aggrecan, link protein).
2. Type II collagen and aggrecan synthesis gene expression is upregulated, restoring the structural matrix components of articular cartilage.
3. Matrix metalloproteinase expression (MMP-1, MMP-3, MMP-13) is downregulated, reducing enzymatic cartilage degradation.
4. TIMP (tissue inhibitor of metalloproteinases) expression is normalized, further protecting the cartilage matrix from proteolytic destruction.
5. SOX9 transcription factor expression is supported, maintaining chondrocyte phenotype and preventing dedifferentiation toward fibroblast-like cells.

Joint & Bone Research

• Osteoarthritis: In OA models, Cartalax course administration preserved cartilage thickness and reduced Mankin histological scores compared to untreated controls.
• Bone Density: Cartalax also modulates osteoblast gene expression, with modest improvements in bone mineral density reported in aged rodent models.
• Post-Injury: After cartilage or joint injury, Cartalax may support the repair process by enhancing chondrocyte synthetic activity during the recovery window.
• Combination: Often combined with Sigumir (musculoskeletal complex bioregulator) for comprehensive joint and bone support protocols.
• Protocol: 1–2 capsules daily for 20–30 days. Particularly relevant for individuals over 40 or those with history of joint injury or repetitive joint stress.